<DOC>
	<DOCNO>NCT00473408</DOCNO>
	<brief_summary>The purpose current trial explore whether standard treatment radiotherapy temozolomide affect tumor vasculature patient high-grade astrocytomas . If vascular effect identify , future clinical trial propose wherein anti-angiogenic agent added increase patient survival .</brief_summary>
	<brief_title>The Effect Radiotherapy Temozolomide Tumor Vasculature Stem Cells Human High-grade Astrocytomas</brief_title>
	<detailed_description>Today 's standard treatment radiotherapy temozolomide yield life expectancy 1.5-3 year patient high-grade astrocytomas . Thus , need therapeutic improvement patient population . The purpose current trial explore whether radiotherapy temozolomide affect tumor vasculature patient high-grade astrocytomas . If vascular effect identify , future clinical trial propose wherein anti-angiogenic agent added increase patient survival . Additionally , stem cell within malignant brain tumor important new area research patient population , investigation herein could contribute identify new predictive marker therapeutic target . Primary objective : To assess vascular perfusion permeability characteristic high-grade astrocytomas ( anaplastic astrocytoma glioblastoma multiforme ) use dynamic contrast-enhanced magnetic resonance imaging ( DCE-MRI ) patient receive radiotherapy temozolomide . Furthermore ass whether therapy-induced change tumor perfusion correlate progression-free survival . Secondary objective : - Analyze circulate endothelial cell blood flow cytometry explore whether cell use indirect estimate angiogenesis high-grade astrocytomas - Analyze tumor specimens patient gliomas debulked commence therapy - immunostaining tumor vasculature assess microvessel density - immunostaining tumor stem cell - flow cytometric assessment dissolve tumor tissue look tumor stem cell - Assess progression-free survival patient include study , order correlate survival data tissue sample result .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>Histologically confirm primary highgrade astrocytoma , i.e . anaplastic astrocytoma glioblastoma multiforme . Have WHO performance status 02 able undergo outpatient treatment . Age â‰¥18 year . No pregnant lactating patient include . Patients must radiographically document measurable disease postoperatively . At least one tumor lesion must unidimensionally measurable follow : Tumor lesion &gt; 10 mm conventional MRI scan , T1weighted series , intravenous ( i.v . ) gadolinium chelate contrast . All diagnostic radiology study must perform within 28 day prior registration . Absence condition make MRI scan impossible ; Cardiac pacemaker Other ferromagnetic metal implant authorise use MRI type cerebral aneurysm clip Serious claustrophobia Obesity ( &gt; 300 lb. , 140 Kg ) Patients receive corticosteroid receive stable decreasing dos least 14 day enter trial . No prior chemotherapy highgrade astrocytoma Absence opportunistic infection make temozolomide contraindicate . Minimum required laboratory data : Hematology : Absolute granulocytes &gt; 1.0 x 10^9/L Platelets &gt; 100 x 10^9/L Biochemistry : Bilirubin &lt; 1.5 x upper normal limit INR &lt; 1.5 Serum creatinine &lt; 1.5 x upper normal limit Adequate cognitive function order give inform consent . Absence psychological , familial sociological condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Before patient registration/randomization , write informed consent must give accord national local regulation . Lack fulfillment inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Glioma</keyword>
	<keyword>DCE-MRI</keyword>
	<keyword>Angiogenesis</keyword>
	<keyword>Cancer stem cell</keyword>
	<keyword>Tumor vasculature</keyword>
</DOC>